CONTRACTOR: MAYO CLINIC; DUNNS: 006471700; PILOT STUDY OF EGFR INHIBITION WITH ERLOTINIB IN CIRRHOSIS TO INHIBIT FIRBROGENESIS AND PREVENT HEPATOCELLULAR CARCINOMA HHSN261201200042I; TASK ORDER HHSN26

承包商：梅奥诊所；

• 批准号: 8948670
• 负责人: PAUL J LIMBURG
• 金额: $ 47.17万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-05 至 2017-09-04
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8948670
• 关键词: Adverse event; Animal Model; Cirrhosis; Clinic; Clinical Trials; Contractor; Dose; Epidermal Growth Factor; Epidermal Growth Factor Receptor; Erlotinib; Excision; Gene Expression Profile; Hepatitis C; Hepatitis C virus; Intervention; Liver; Measurable; Organ; Participant; Patients; Pilot Projects; Plasma; Primary carcinoma of the liver cells; Receptor Signaling; Schedule; Staining method; Stains; Tissues; Viral Load result; design; outcome forecast; overexpression; prevent; response

The proposed Pilot, dose ranging clinical trial is designed to identify the lowest safe and minimum effective dose (MED) of daily erlotinib that inhibits epidermal growth factor receptor (EGFR) signaling in the target organ (liver) as assessed by phospho‐EGFR staining. Epidermal growth factor (EGF) expression is associated with progression of cirrhosis, and in animal models, overexpression of EGF in liver tissue leads to formation of hepatocellular carcinoma

拟议的试点、剂量范围临床试验旨在通过磷酸化表皮生长因子受体(EGFR)染色评估，确定每日最低安全和最低有效剂量(MED)的厄洛替尼抑制靶器官(肝脏)中的表皮生长因子受体(EGFR)信号。表皮生长因子(EGF)的表达与肝硬变的进展有关，在动物中 肝组织中EGF过度表达导致肝细胞癌的形成